Abstract | BACKGROUND: METHODS: Immune-mediated corneal neovascularization was created in 36 right eyes of 36 rabbits. The rabbits were then randomized into four groups. Group I received CsA 0.05%, Group II received dexamethasone 0.1%, Group III received bevacizumab 0.5%, and Group IV received isotonic saline twice a day for 14 days. The corneal surface covered with neovascular vessels was measured on the photographs. The rabbits were then sacrificed and the corneas excised. Paraffin-embedded sections were stained with hematoxylin- eosin and terminal deoxynucleotidyl transferase-mediated dUTP- biotin nick end labeling assay. RESULTS: The means of percent area of corneal neovascularization in Group I, II, III, and IV were 24.4%, 5.9%, 37.1%, and 44.1%, respectively. The inhibitory effect of CsA 0.05% was found to be better than the effect found in the bevacizumab 0.5% and control groups (p = 0.03 and p = 0.02, respectively). CsA 0.05% was found to have significantly lesser inhibitory effects on corneal neovascularization than dexamethasone 0.1% (p < 0.001). Apoptotic cell density was higher in Group III and Group IV than in Group I and Group II. There was no difference between Group I and Group II in terms of apoptotic cell density (p = 0.7). CONCLUSIONS:
|
Authors | Yasin Yücel Bucak, Mesut Erdurmus, Elçin Hakan Terzi, Aysel Kükner, Serdal Çelebi |
Journal | Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
(Graefes Arch Clin Exp Ophthalmol)
Vol. 251
Issue 11
Pg. 2555-61
(Nov 2013)
ISSN: 1435-702X [Electronic] Germany |
PMID | 24048578
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- 5-(3-(1-(5-(5-(biotinylamino)pentanamidomethyl)-2-nitrophenyl)ethoxycarbonylamino)propenyl)-2'-deoxyuracil 5'-triphosphate
- Angiogenesis Inhibitors
- Antibodies, Monoclonal, Humanized
- Deoxyuracil Nucleotides
- Glucocorticoids
- Immunosuppressive Agents
- Ophthalmic Solutions
- Serum Albumin, Bovine
- Bevacizumab
- Biotin
- Dexamethasone
- Cyclosporine
|
Topics |
- Administration, Topical
- Angiogenesis Inhibitors
(administration & dosage)
- Animals
- Antibodies, Monoclonal, Humanized
(administration & dosage)
- Apoptosis
- Arthus Reaction
(drug therapy, immunology)
- Bevacizumab
- Biotin
(analogs & derivatives)
- Corneal Neovascularization
(drug therapy, immunology)
- Cyclosporine
(administration & dosage)
- Deoxyuracil Nucleotides
- Dexamethasone
(administration & dosage)
- Disease Models, Animal
- Glucocorticoids
(administration & dosage)
- Immunoenzyme Techniques
- Immunosuppressive Agents
(administration & dosage)
- In Situ Nick-End Labeling
- Ophthalmic Solutions
- Rabbits
- Serum Albumin, Bovine
(immunology)
|